Quest Diagnostics Inc. (DGX)
Why Quest Diagnostics (DGX) is Poised to Beat Earnings Estimates Again
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Hold Quest Diagnostics Stock in Your Portfolio Now?
DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.
New Health Coaching Service on questhealth.com Set to Boost DGX Stock
Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health.
Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.
DGX vs. PNTG: Which Stock Is the Better Value Option?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Quest Diagnostics (DGX) and The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks?
Here's Why You Should Retain DGX Stock in Your Portfolio Now
Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base
Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLabs acquisition, aims to expand its footprint and diversify operations, despite short-term EPS dilution. The company faces risks from PAMA reimbursement cuts and labor market challenges but expects long-term growth from organic and acquisition activities.
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusting my Buy Threshold to $150 and Sell Target to $227.
DGX or PNTG: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks?
